Dilaudid Injection

  • Narcotic analgesics

Dilaudid Injection Generic Name & Formulations

General Description

Hydromorphone HCl 0.5mg/0.5mL, 1mg/mL, 2mg/mL; soln for IV, IM or SC inj; preservative-free; contains sulfites.

Pharmacological Class

Opioid agonist.

How Supplied

Prefilled syringes—10, 24; HPF Injection—contact supplier


Dilaudid Injection Indications


Management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate.

Limitations of Use

Reserve for use in patients for whom alternative treatment options have not been tolerated or not provided adequate analgesia.

Dilaudid Injection Dosage and Administration


Use lowest effective dose for shortest duration. Individualize. Initially 1–2mg SC or IM, or 0.2–1mg by slow IV (at least 2–3mins) every 2–3 hours as needed. Elderly, debilitated: initially 0.2mg IV. Renal or hepatic impairment: initially ¼ to ½ the usual dose. Conversion from other opioids: see full labeling. Withdraw gradually by 25–50% every 2–4 days.


Not established.

Dilaudid Injection Contraindications


Significant respiratory depression. Acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment. Known or suspected GI obstruction, including paralytic ileus. Hydromorphone-HPF: opioid non-tolerant.

Dilaudid Injection Boxed Warnings

Boxed Warning

Addiction, abuse, and misuse. Life-threatening respiratory depression. Neonatal opioid withdrawal syndrome. Risks from concomitant use with benzodiazepines and other CNS depressants.

Dilaudid Injection Warnings/Precautions


Abuse potential (monitor). Life-threatening respiratory depression; monitor within first 24–72hrs of initiating therapy and following dose increases. Sleep-related breathing disorders (including central sleep apnea (CSA), sleep-related hypoxemia); consider dose reduction if CSA develops. COPD, cor pulmonale, decreased respiratory reserve, hypoxia, hypercapnia, or pre-existing respiratory depression; monitor and consider non-opioid analgesics. Adrenal insufficiency. Head injury. Increased intracranial pressure, brain tumors; monitor. Seizure disorders. CNS depression. Impaired consciousness, coma, shock; avoid. Biliary tract disease. Acute pancreatitis. Drug abusers. Renal or hepatic impairment. Reevaluate periodically. Avoid abrupt cessation. Elderly. Cachectic. Debilitated. Pregnancy; potential neonatal opioid withdrawal syndrome during prolonged use. Labor & delivery: not recommended. Nursing mothers: monitor infants.

Dilaudid Injection Pharmacokinetics

See Literature

Dilaudid Injection Interactions


Increased risk of hypotension, respiratory depression, sedation with benzodiazepines or other CNS depressants (eg, non-benzodiazepine sedatives/hypnotics, anxiolytics, general anesthetics, phenothiazines, tranquilizers, muscle relaxants, antipsychotics, alcohol, other opioids); reserve concomitant use in those for whom alternative options are inadequate; limit dosages/durations to minimum required; monitor. During or within 14 days of MAOIs: not recommended. Risk of serotonin syndrome with serotonergic drugs (eg, SSRIs, SNRIs, TCAs, triptans, 5-HT3 antagonists, mirtazapine, trazodone, tramadol, cyclobenzaprine, metaxalone, MAOIs, linezolid, IV methylene blue); monitor and discontinue if suspected. Avoid concomitant mixed agonist/antagonist opioids (eg, butorphanol, nalbuphine, pentazocine) or partial agonist (eg, buprenorphine); may reduce effects and/or precipitate withdrawal symptoms. May antagonize diuretics; monitor. Paralytic ileus may occur with anticholinergics.

Dilaudid Injection Adverse Reactions

Adverse Reactions

Lightheadedness, dizziness, sedation, nausea, vomiting, sweating, flushing, dysphoria, euphoria, dry mouth, pruritus; respiratory depression, severe hypotension, syncope.

Dilaudid Injection Clinical Trials

See Literature

Dilaudid Injection Note

Not Applicable

Dilaudid Injection Patient Counseling

See Literature